New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
07:04 EDTEBSEmergent announces waiting period expiration for Cangene acquisition
Emergent BioSolutions announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, in connection with Emergentís proposed acquisition of Cangene has expired. The expiration of the waiting period for antitrust review of the proposed acquisition satisfies one of the conditions to the closing of the acquisition. As announced on December 11, 2013, Emergent and Cangene have entered into a definitive agreement under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222M. Completion of the acquisition is subject to approval by 66 2/3% of the votes cast by Cangene shareholders at a special shareholder meeting scheduled for February 12, approval by the Ontario Superior Court of Justice at a hearing scheduled for February 18 and other customary closing conditions. The transaction is expected to close before the end of1Q14.
News For EBS From The Last 14 Days
Check below for free stories on EBS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
17:33 EDTEBSEmergent BioSolutions, MorphoSys sign license agreement for ES414
Subscribe for More Information
August 7, 2014
16:23 EDTEBSEmergent BioSolutions sees Q3 revenue $110M-$125M, consensus $125.17M
Subscribe for More Information
16:22 EDTEBSEmergent BioSolutions raises FY14 revenue view to $425-$450M from $415M-$445M
Subscribe for More Information
16:20 EDTEBSEmergent BioSol' reports Q2 GAAP EPS 13c, may not compare with consensus 32c
Reports Q2 revenue $110.3M, consensus $109.25M.
07:13 EDTEBSEmergent BioSolutions submits BLA to FDA for AIGIV
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use